Evaxion A/S (EVAX) surged 27.27 percent to $4.20 on Thursday, gaining $0.79, after announcing it has out-licensed its vaccine candidate EVX-B3 to Merck & Co. (MSD) under a previously signed option and license agreement. The deal includes a $7.5 million upfront payment, upto $592 million in potential milestones, and royalties on net sales.
The stock opened at $4.28 and traded between $3.91 and $4.75, compared with a prior close of $3.30 on the Nasdaq.
Trading volume spiked to 71.4 million shares, well above the average of 92,139. Evaxion now trades within a 52-week range of $1.20 to $16.10.
4.2000+0.9000(+27.2727%)
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.